EUCTR2005-003048-78-IT进行中（未招募）不适用
A 9-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, STUDY OF PREGABALIN BID IN SUBJECTS WITH POSTTRAUMATIC PERIPHERAL NEUROPATHIC PAI
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- PFIZER
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A 17-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER TRIAL OF PREGABALIN FOR THE TREATMENT OF CHRONIC CENTRAL NEUROPATHIC PAIN AFTER SPINAL CORD INJURYChronic Central Neuropathic Pain after Spinal Cord Injury.MedDRA version: 9.1Level: LLTClassification code 10054095Term: Neuropathic painEUCTR2008-008339-27-CZPfizer Inc., 235 East 42nd Street, New York, NY10017200
进行中（未招募）
不适用
A 14-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PREGABALIN TWICE DAILY IN PATIENTS WITH FIBROMYALGIA - NDTreatment of fibromyalgiaMedDRA version: 6.1Level: PTClassification code 10048439MedDRA version: 9.1Level: LLTClassification code 10048439Term: FibromyalgiaEUCTR2006-000425-57-ITPFIZER740
已完成
不适用
A 4-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF L-000904218 IN PATIENTS WITH KNEE OR HIP OSTEOARTHRITIS-M169 Coxarthrosis, unspecified-M179 Gonarthrosis, unspecifiedCoxarthrosis, unspecifiedGonarthrosis, unspecifiedM169M179PER-072-05MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
不适用
A 6-WEEK STUDY OF LURASIDONE ADJUNCTIVE TO LITHIUM ORDIVALPROEX FOR THE TREATMENT OF BIPOLARDEPRESSION IN SUBJECTS NOT RESPONDING TO TREATMENT WITH LITHIUM OR DIVALPROEX ALONEBipolar disorderEUCTR2010-019778-34-LTSunovion Pharmaceuticals Inc.340
进行中（未招募）
1 期
The purpose of this research study is to evaluate the safety and effectiveness of lurasidone (20 mg/day to 80 mg/day) compared to a placebo for use in children and adolescent subjects with bipolar I depression.Bipolar I depressionMedDRA version: 17.1Level: LLTClassification code 10004936Term: Bipolar depressionSystem Organ Class: 100000004873EUCTR2013-004903-37-DESUNOVION PHARMACEUTICALS INC.340